Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype In Vivo

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3358-3368

  Spickler, Catherine ^a,d   Lippens, Julie ^a   Laberge, Marie Kristine ^a   Desmeules, Sophie ^a,e   Bellavance, Édith ^a   Garneau, Michel ^a   Guo, Tim ^a   Hucke, Oliver ^a,f   Leyssen, Pieter ^b   Neyts, Johan ^b   Vaillancourt, Fréderic H ^a,g   Décor, Anne ^a,h   O'Meara, Jeff ^a,i   Franti, Michael ^a,e   Gauthier, Annick ^a,c  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c MCGILL UNIVERSITY   (Canada)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g EISAI INC   (United States)

^h BAYER AG   (Germany)

ⁱ Alphora Research Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIINOTHIAZOLE; AMINO ACID; ANTIVIRUS AGENT; ENVIROXIME; ENZYME INHIBITOR; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOTRANSFERASE; SMALL INTERFERING RNA; THIAZOLE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MORTALITY; MOUSE; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RHINOVIRUS; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS INHIBITION; VIRUS REPLICATION;

1-PHOSPHATIDYLINOSITOL 4-KINASE; ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL LINE, TUMOR; CEPHALOSPORINS; COMMON COLD; FEMALE; HELA CELLS; HUMANS; MICE; POLYMORPHISM, SINGLE NUCLEOTIDE; RHINOVIRUS; RNA INTERFERENCE; RNA, SMALL INTERFERING; THIAZOLES; VIRUS REPLICATION;

EID: 84879021404     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00303-13     Document Type: Article

References (65)

1. Simmonds P, McIntyre C, Savolainen-Kopra C, Tapparel C, Mackay IM, Hovi T. 2010. Proposals for the classification of human rhinovirus species C into genotypically assigned types. J. Gen. Virol. 91:2409-2419.
2. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O'Toole S, Myint SH, Tyrrell DA. 1995. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 310:1225-1229.
3. Olenec JP, Kim WK, Lee WM, Vang F, Pappas TE, Salazar LE, Evans MD, Bork J, Roberg K, Lemanske RF, Jr, Gern JE. 2010. Weekly monitoring of children with asthma for infections and illness during common cold seasons. J. Allergy Clin. Immunol. 125:1001-1006.
4. Atmar RL, Guy E, Guntupalli KK, Zimmerman JL, Bandi VD, Baxter BD, Greenberg SB. 1998. Respiratory tract viral infections in inner-city asthmatic adults. Arch. Intern. Med. 158:2453-2459. (Pubitemid 28555504)
5. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedzicha JA. 2001. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164:1618-1623. (Pubitemid 33124148)
6. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebadze T, Contoli M, Sanderson G, Kon OM, Papi A, Jeffery PK, Stanciu LA, Johnston SL. 2008. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc. Natl. Acad. Sci. U. S. A. 105:13562-13567.
7. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, Aniscenko J, Laza-Stanca V, Edwards MR, Slater L, Papi A, Stanciu LA, Kon OM, Johnson M, Johnston SL. 2011. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am. J. Respir. Crit. Care Med. 183:734-742.
8. Rohde G. 2009. Drug targets in rhinoviral infections. Infect. Disord. Drug Targets 9:126-132.
9. Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ, III, Zalman LS, Burns-Naas LA, Tran JQ. 2005. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 49:2267-2275. (Pubitemid 40734453)
10. Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 43:2444-2450. (Pubitemid 29471225)
11. Tan J, George S, Kusov Y, Perbandt M, Anemuller S, Mesters JR, Norder H, Coutard B, Lacroix C, Leyssen P, Neyts J, Hilgenfeld R. 2013. 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J. Virol. 87:4339-4351.
12. Hayden FG, Gwaltney JM, Jr. 1982. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob. Agents Chemother. 21:892-897. (Pubitemid 12012603)
13. Phillpotts RJ, Jones RW, Delong DC, Reed SE, Wallace J, Tyrrell DA. 1981. The activity of enviroxime against rhinovirus infection in man. Lancet i:1342-1344. (Pubitemid 11114484)
14. Miller FD, Monto AS, Delong DC, Exelby A, Bryan ER, Srivastava S. 1985. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob. Agents Chemother. 27:102-106. (Pubitemid 15198163)
15. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2011. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J. Virol. 85:2364-2372.
16. Hayden FG, Hipskind GJ, Woerner DH, Eisen GF, Janssens M, Janssen PA, Andries K. 1995. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob. Agents Chemother. 39:290-294.
17. Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, Liu S, Hudson S, Pevear DC, Collett M, McKinlay M. 2003. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin. Infect. Dis. 36:1523-1532. (Pubitemid 36783334)
18. Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS. 2005. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob. Agents Chemother. 49:4492-4499. (Pubitemid 41552577)
19. Biota Holdings Limited. 28 March 2012. HRV phase IIb study achieves primary endpoint. Biota Holdings Limited, Notting Hill, Victoria, Australia. http://www.biota.com.au/uploaded/154/1021819-20hrvphaseiibstudyachieve.pdf.
20. Feil SC, Hamilton S, Krippner GY, Lin B, Luttick A, McConnell DB, Nearn R, Parker MW, Ryan J, Stanislawski PC, Tucker SP, Watson KG, Morton CJ. 2012. An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus. ACS Med. Chem. Lett. 3:303-307.
21. Lau SK, Yip CC, Tsoi HW, Lee RA, So LY, Lau YL, Chan KH, Woo PC, Yuen KY. 2007. Clinical features and complete genome characterization of a distinct human rhinovirus (HRV) genetic cluster, probably representing a previously undetected HRV species, HRV-C, associated with acute respiratory illness in children. J. Clin. Microbiol. 45:3655-3664. (Pubitemid 350156863)
22. McErlean P, Shackelton LA, Andrews E, Webster DR, Lambert SB, Nissen MD, Sloots TP, Mackay IM. 2008. Distinguishing molecular features and clinical characteristics of a putative new rhinovirus species, human rhinovirus C (HRV C). PLoS One 3:e1847. doi:10.1371/journal.pone.0001847. (Pubitemid 351943837)
23. Ashraf S, Brockman-Schneider R, Bochkov YA, Pasic TR, Gern JE. 2013. Biological characteristics and propagation of human rhinovirus-C in differentiated sinus epithelial cells. Virology 436:143-149.
24. Bochkov YA, Palmenberg AC, Lee WM, Rathe JA, Amineva SP, Sun X, Pasic TR, Jarjour NN, Liggett SB, Gern JE. 2011. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nat. Med. 17:627-632.
25. Hao W, Bernard K, Patel N, Ulbrandt N, Feng H, Svabek C, Wilson S, Stracener C, Wang K, Suzich J, Blair W, Zhu Q. 2012. Infection and propagation of human rhinovirus C in human airway epithelial cells. J. Virol. 86:13524-13532.
26. Huang T, Wang W, Bessaud M, Ren P, Sheng J, Yan H, Zhang J, Lin X, Wang Y, Delpeyroux F, Deubel V. 2009. Evidence of recombination and genetic diversity in human rhinoviruses in children with acute respiratory infection. PLoS One 4:e6355. doi:10.1371/journal.pone.0006355.
27. Iwane MK, Prill MM, Lu X, Miller EK, Edwards KM, Hall CB, Griffin MR, Staat MA, Anderson LJ, Williams JV, Weinberg GA, Ali A, Szilagyi PG, Zhu Y, Erdman DD. 2011. Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J. Infect. Dis. 204:1702-1710.
28. Bizzintino J, Lee WM, Laing IA, Vang F, Pappas T, Zhang G, Martin AC, Khoo SK, Cox DW, Geelhoed GC, McMinn PC, Goldblatt J, Gern JE, Le Souef PN. 2011. Association between human rhinovirus C and severity of acute asthma in children. Eur. Respir. J. 37:1037-1042.
29. Miller EK, Edwards KM, Weinberg GA, Iwane MK, Griffin MR, Hall CB, Zhu Y, Szilagyi PG, Morin LL, Heil LH, Lu X, Williams JV. 2009. Anovel group of rhinoviruses is associated with asthma hospitalizations. J. Allergy Clin. Immunol. 123:98-104.
30. Piralla A, Rovida F, Campanini G, Rognoni V, Marchi A, Locatelli F, Gerna G. 2009. Clinical severity and molecular typing of human rhinovirus C strains during a fall outbreak affecting hospitalized patients. J. Clin. Virol. 45:311-317.
31. Lee WM, Lemanske RF, Jr, Evans MD, Vang F, Pappas T, Gangnon R, Jackson DJ, Gern JE. 2012. Human rhinovirus species and season of infection determine illness severity. Am. J. Respir. Crit. Care Med. 186: 886-891.
32. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
33. Canadian Council of Animal Care. 1993. Guide to the care and use of experimental animals, vol 1, 2nd ed. Canadian Council of Animal Care, Ottawa, Ontario, Canada.
34. De Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Al-Tel TH, De Clercq E, van Kuppeveld F, Neyts J. 2009. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 53:1850-1857.
35. Lu X, Holloway B, Dare RK, Kuypers J, Yagi S, Williams JV, Hall CB, Erdman DD. 2008. Real-time reverse transcription-PCR assay for comprehensive detection of human rhinoviruses. J. Clin. Microbiol. 46:533-539. (Pubitemid 351231298)
36. McKnight KL, Lemon SM. 1996. Capsid coding sequence is required for efficient replication of human rhinovirus 14 RNA. J. Virol. 70:1941-1952. (Pubitemid 26062959)
37. Andries K, Dewindt B, Snoeks J, Willebrords R, van Eemeren K, Stokbroekx R, Janssen PA. 1992. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob. Agents Chemother. 36:100-107.
38. Binford SL, Weady PT, Maldonado F, Brothers MA, Matthews DA, Patick AK. 2007. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 51: 4366-4373. (Pubitemid 350209891)
39. Vaillancourt FH, Brault M, Pilote L, Uyttersprot N, Gaillard ET, Stoltz JH, Knight BL, Pantages L, McFarland M, Breitfelder S, Chiu TT, Mahrouche L, Faucher AM, Cartier M, Cordingley MG, Bethell RC, Jiang H, White PW, Kukolj G. 2012. Evaluation of phosphatidylinositol-4-kinase III alpha as a hepatitis C virus drug target. J. Virol. 86:11595-11607.
40. Heinz BA, Vance LM. 1995. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 69:4189-4197.
41. Heinz BA, Vance LM. 1996. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J. Virol. 70: 4854-4857. (Pubitemid 26187489)
42. Hsu NY, Ilnytska O, Belov G, Santiana M, Chen YH, Takvorian PM, Pau C, van der Schaar H, Kaushik-Basu N, Balla T, Cameron CE, Ehrenfeld E, van Kuppeveld FJ, Altan-Bonnet N. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799-811.
43. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM. 2006. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733-747.
44. Altan-Bonnet N, Balla T. 2012. Phosphatidylinositol 4-kinases: hostages harnessed to build panviral replication platforms. Trends Biochem. Sci. 37:293-302.
45. Delang L, Paeshuyse J, Neyts J. 2012. The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. Biochem. Pharmacol. 84:1400-1408.
46. Greninger AL, Knudsen GM, Betegon M, Burlingame AL, DeRisi JL. 2012. The 3A protein from multiple picornaviruses utilizes the Golgi adaptor protein ACBD3 to recruit PI4KIII beta. J. Virol. 86:3605-3616.
47. Sasaki J, Ishikawa K, Arita M, Taniguchi K. 2012. ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sites. EMBO J. 31:754-766.
48. Vaillancourt FH, Pilote L, Cartier M, Lippens J, Liuzzi M, Bethell RC, Cordingley MG, Kukolj G. 2009. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology 387:5-10.
49. Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, Leighton-Davies J, Wilson CJ, Myer V, Cornellataracido I, Baryza J, Tallarico J, Joberty G, Bantscheff M, Schirle M, Bouwmeester T, Mathy JE, Lin K, Compton T, Labow M, Wiedmann B, Gaither LA. 2009. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J. Virol. 83:10058-10074.
50. Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G. 2009. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. U. S. A. 106:7577-7582.
51. Berger KL, Kelly SM, Jordan TX, Tartell MA, Randall G. 2011. Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J. Virol. 85:8870-8883.
52. Martin-Acebes MA, Blazquez AB, Jimenez de Oya N, Escribano-Romero E, Saiz JC. 2011. West Nile virus replication requires fatty acid synthesis but is independent on phosphatidylinositol-4-phosphate lipids. PLoS One 6:e24970. doi:10.1371/journal.pone.0024970.
53. Yang N, Ma P, Lang J, Zhang Y, Deng J, Ju X, Zhang G, Jiang C. 2012. Phosphatidylinositol 4-kinase III beta is required for severe acute respiratory syndrome coronavirus spike-mediated cell entry. J. Biol. Chem. 287: 8457-8467.
54. Balla A, Balla T. 2006. Phosphatidylinositol 4-kinases: old enzymes with emerging functions. Trends Cell Biol. 16:351-361. (Pubitemid 44062315)
55. Godi A, Pertile P, Meyers R, Marra P, Di Tullio G, Iurisci C, Luini A, Corda D, De Matteis MA. 1999. ARF mediates recruitment of PtdIns-4-OH kinase-beta and stimulates synthesis of PtdIns(4,5)P2 on the Golgi complex. Nat. Cell Biol. 1:280-287. (Pubitemid 129495778)
56. Toth B, Balla A, Ma H, Knight ZA, Shokat KM, Balla T. 2006. Phosphatidylinositol 4-kinase III beta regulates the transport of ceramide between the endoplasmic reticulum and Golgi. J. Biol. Chem. 281:36369-36377. (Pubitemid 46041371)
57. Flanagan CA, Schnieders EA, Emerick AW, Kunisawa R, Admon A, Thorner J. 1993. Phosphatidylinositol 4-kinase: gene structure and requirement for yeast cell viability. Science 262:1444-1448. (Pubitemid 24035066)
58. Sridhar S, Patel B, Aphkhazava D, Macian F, Santambrogio L, Shields D, Cuervo AM. 2013. The lipid kinase PI4KIII beta preserves lysosomal identity. EMBO J. 32:324-339.
59. Arita M, Wakita T, Shimizu H. 2009. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J. Gen. Virol. 90:1869-1879.
60. van der Schaar HM, van der Linden L, Lanke KH, Strating JR, Purstinger G, de Vries E, de Haan CA, Neyts J, van Kuppeveld FJ. 2012. Coxsackievirus mutants that can bypass host factor PI4KIII beta and the need for high levels of PI4P lipids for replication. Cell Res. 22:1576-1592.
61. Bittner RE, Anderson LV, Burkhardt E, Bashir R, Vafiadaki E, Ivanova S, Raffelsberger T, Maerk I, Hoger H, Jung M, Karbasiyan M, Storch M, Lassmann H, Moss JA, Davison K, Harrison R, Bushby KM, Reis A. 1999. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat. Genet. 23:141-142. (Pubitemid 29455382)
62. Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB, Bohlega S, Culper EJ, Amato AA, Bossie K, Oeltjen J, Bejaoui K, McKenna-Yasek D, Hosler BA, Schurr E, Arahata K, de Jong PJ, Brown RH, Jr. 1998. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 20:31-36. (Pubitemid 28410339)
63. Rayavarapu S, Van der Meulen JH, Gordish-Dressman H, Hoffman EP, Nagaraju K, Knoblach SM. 2010. Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. PLoS One 5:e12981. doi:10.1371/journal.pone.0012981.
64. Lamarche MJ, Borawski J, Bose A, Capacci-Daniel C, Colvin R, Dennehy M, Ding J, Dobler M, Drumm J, Gaither LA, Gao J, Jiang X, Lin K, McKeever U, Puyang X, Raman P, Thohan S, Tommasi R, Wagner K, Xiong X, Zabawa T, Zhu S, Wiedmann B. 2012. Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob. Agents Chemother. 56:5149-5156.
65. Décor A, Grand-Maître C, Hucke O, O'Meara J, Kuhn C, Constantineau-Forget L, Brochu C, Malenfant E, Bertrand-Laperle M, Bordeleau J, Ghiro E, Pesant M, Fazal G, Gorys V, Little M, Boucher C, Bordeleau S, Turcotte P, Guo T, Garneau M, Spickler C, Gauthier A. 7 May 2013, posting date. Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus. Bioorg. Med. Chem. Lett. doi:10.1016/j.bmcl.2013.04.077.